Daiwa: Raised Shanghai Pharmaceutical's target price to HK$18. Rated as "Buy".

According to the Securities Times APP, Morgan Stanley released a research report stating that the target price for Shanghai Pharmaceuticals (02607.HK) has been raised from 17 Hong Kong dollars to 18 Hong Kong dollars, equivalent to a forecasted 2026 P/E ratio of 9.7 times, with a rating of "buy". Taking into account the mid-term performance earnings, the bank has raised Shanghai Pharmaceuticals' profit forecast for 2025 to 2030 by 1 to 11%, citing increased sales in distribution and manufacturing businesses.